Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06065228 · ClinicalTrials.gov registry record

Therapeutic Endpoint in Pediatric IBD Conditions

A clinical trial of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Children's National Research Institute.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT06065228 is a study of Crohn Disease and Inflammatory Bowel Diseases that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 60 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06065228, a study of Crohn Disease and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Children's National Research Institute.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.

Interventions

  • OTHER AlgometRx Nociometer

Study Locations (1)

District of Columbia

  • Children's National Health System - Washington D.C.

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-11-27
Est. Completion 2025-12

What the Registry Record Tells You About NCT06065228

The ClinicalTrials.gov registry entry for NCT06065228 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which AlgometRx Nociometer is the first listed.

NCT06065228 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06065228 about?

NCT06065228 is a clinical study titled "Therapeutic Endpoint in Pediatric IBD Conditions". The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory respon...

What is the current status of trial NCT06065228?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2023-11-27. Estimated completion is 2025-12.

What conditions does trial NCT06065228 study?

This clinical trial studies the following conditions: Crohn Disease, Inflammatory Bowel Diseases, Colitis, Ulcerative.

What interventions are being tested in trial NCT06065228?

The interventions under investigation include: AlgometRx Nociometer (OTHER).

Who is sponsoring clinical trial NCT06065228?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06065228 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.